Alitretinoin oral - Stiefel Laboratories
Alternative Names: Alitoc; Alitretinoin - Basilea; BAL-4979; BAL4079; Cehado; Once-daily oral alitretinoin - Basilea; ToctinoLatest Information Update: 29 Jan 2026
At a glance
- Originator Basilea Pharmaceutica
- Developer Basilea Pharmaceutica; Stiefel Laboratories
- Class Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
- Mechanism of Action Retinoic acid receptor agonists; Retinoid X receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Eczema
- No development reported Skin disorders
- Discontinued Palmoplantar pustulosis; Systemic lupus erythematosus
Most Recent Events
- 29 Jan 2026 No development reported - Phase-III for Skin disorders (In the elderly, In adults) in Germany (PO)
- 22 Jan 2019 Launched for Eczema in Slovenia (PO)
- 21 Jan 2016 Discontinued - Phase-III for Eczema in USA (PO)